Search - tctmd.com

Displaying 501 - 520 of 1120

Sort: Relevancy | Date

News Daily News

Rural-Urban Gap Widens for Cardiometabolic Health Disparities

Michael O'Riordan

June 22, 2020

News Daily News

Most Stable Angina Patients Not Taking First-line Meds

Shelley Wood

June 18, 2020

News Daily News

Hydroxychloroquine Fails to Prevent COVID-19 in Those Exposed to the Virus: RCT

Caitlin E. Cox

June 05, 2020

News Daily News

Lancet COVID-19 Hydroxychloroquine Study Faces ‘Data Integrity’ Questions

Michael O'Riordan

May 29, 2020

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

News Daily News

More Evidence of Lower Fracture Risk With DOACs Versus Warfarin

Todd Neale

May 19, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Features

Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes

Michael O'Riordan

May 12, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

L.A. McKeown

April 01, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Presentation ACC 2020

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Presenter: Frederick Raal

March 30, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

Advertisement

Rural-Urban Gap Widens for Cardiometabolic Health Disparities

Most Stable Angina Patients Not Taking First-line Meds

Hydroxychloroquine Fails to Prevent COVID-19 in Those Exposed to the Virus: RCT

Lancet COVID-19 Hydroxychloroquine Study Faces ‘Data Integrity’ Questions

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

More Evidence of Lower Fracture Risk With DOACs Versus Warfarin

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content